Avacta opens phase 1 trial for conjugate's efficacy regarding tumours
(Alliance News) - Avacta Group PLC on Monday announced the opening of a phase 1 trial for AVA6103, a peptide-drug conjugate. Read More
| Price | 69.50p on 25-03-2026 at 19:35:08 |
|---|---|
| Change | 2.00p 2.96% |
| Buy | 71.00p |
| Sell | 68.00p |
| Last Trade: | Unknown 49,000.00 at 69.50p |
| Day's Volume: | 1,421,971 |
| Last Close: | 69.50p |
| Open: | 67.50p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 67.50p - 70.50p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £304.16m |
| VWAP: | 69.47p |
| Shares in Issue: | 437.63m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 49,000 | 69.50p | OTC Trade |
17:06:55 - 25-Mar-26 |
| Sell* | 12,000 | 69.25p | Ordinary |
16:29:37 - 25-Mar-26 |
| Buy* | 16,000 | 71.00p | Ordinary |
16:27:33 - 25-Mar-26 |
| Buy* | 10 | 71.00p | SI Trade |
16:18:57 - 25-Mar-26 |
| Sell* | 425 | 69.69p | Ordinary |
16:15:08 - 25-Mar-26 |
| Buy* | 10 | 72.00p | SI Trade |
16:12:47 - 25-Mar-26 |
| Sell* | 7,236 | 69.3965p | Ordinary |
16:10:53 - 25-Mar-26 |
| Buy* | 621 | 70.00p | SI Trade |
16:10:16 - 25-Mar-26 |
| Buy* | 10 | 70.00p | SI Trade |
16:10:16 - 25-Mar-26 |
| Buy* | 714 | 70.00p | SI Trade |
16:10:16 - 25-Mar-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 17th Mar 2026 7:00 am | RNS-R | Presentations of pre|CISION® Platform Candidates |
| 17th Mar 2026 7:00 am | RNS-R | Presentations of pre|CISION® Platform Candidates |
| 16th Mar 2026 7:00 am | RNS | Phase 1 study opening for AVA6103 |
| 16th Mar 2026 7:00 am | RNS | Phase 1 study opening for AVA6103 |
| 24th Feb 2026 7:00 am | RNS | PreCISION payload delivery advantage over ADC |
| 18th Feb 2026 7:00 am | RNS-R | Avacta to Participate in Conference March 2026 |
| 9th Feb 2026 7:00 am | RNS | Appointment of CSO |
| 3rd Feb 2026 7:00 am | RNS | Faridoxorubicin Program Clinical Updates |
| 21st Jan 2026 7:00 am | RNS | FDA Clearance of IND Application for AVA6103 |
| 20th Jan 2026 7:01 am | RNS | Year-end trading update |